our company

About Santaris Pharma A/S®

Santaris continues to innovate our Locked Nucleic Acid (LNA) Drug Platform. We are building on our years of experience in using that technology to discover and develop potent and safe RNA-medicines. Our pipeline of novel RNA-targeted therapeutics is poised to demonstrate the true potential of antisense to bring breakthrough treatments to patients in need. The partnerships we have signed with industry leaders further validate the potential of the LNA Drug Platform and significantly accelerate its future impact on human health.